These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 14682015

  • 1. [Effect and control of oral contraceptive Minesse (15 mkg EE/60 mkg Gestoden) on menstrual cycle and body weight].
    Krŭsteva.
    Akush Ginekol (Sofiia); 2003; 42(5):46-8. PubMed ID: 14682015
    [No Abstract] [Full Text] [Related]

  • 2. [Clinical experiences with femovan (Gynera)].
    Brill K, Düsterberg B, Albring M.
    Ther Umsch; 1990 Dec; 47(12):958-65. PubMed ID: 2096480
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
    Bilotta P, Favilli S.
    Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oral contraception, 1986. Focus on Triphasil.
    Ellsworth H.
    J Reprod Med; 1986 Jun; 31(6 Suppl):559-64. PubMed ID: 3522896
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
    Cremer P, Vekemans M.
    Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
    Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, Petracco A, Peixoto FC, Camargos AF.
    Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
    [Abstract] [Full Text] [Related]

  • 15. Clinical studies with a new, low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol.
    Acta Obstet Gynecol Scand Suppl; 1987 Dec; 144():1-44. PubMed ID: 2964165
    [No Abstract] [Full Text] [Related]

  • 16. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm].
    Milchev N, Terzhumanov R, Grozdanov G, Krumov G.
    Akush Ginekol (Sofiia); 1992 Dec; 31(2):42-3. PubMed ID: 1342561
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [The effect of two low dose oral contraceptive with gestodene on the systems of natural inhibitors of coagulation].
    Uchikova E, Terzhumanov R, Milchev N, Iacheva T.
    Akush Ginekol (Sofiia); 2004 Dec; 43(6):19-23. PubMed ID: 15669648
    [Abstract] [Full Text] [Related]

  • 19. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives.
    Sabatini R, Cagiano R.
    Contraception; 2006 Sep; 74(3):220-3. PubMed ID: 16904415
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.